natgillin/translations-raw huggingface dataset:
In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab antibody development in patients receiving adalimumab was 3.3%.
Delež pediatričnih bolnikov z zmerno do hudo aktivno Crohnovo boleznijo pri bolnikih, ki so prejeli adalimumab in razvili protitelesa proti adalimumabu, je bil 3,3 %.
In patients with multiple myeloma, the combination of dexamethasone with thalidomide and its analogues is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) (see sections 4.5 and 4.8).
Kombinacija deksametazona in talidomida ter njegovih analogov lahko pri bolnikih z multiplim mielomom poveča tveganje za vensko trombembolijo (predvsem za globoko vensko trombozo in pljučno embolijo) ter arterijsko trombembolijo (predvsem za srčni infarkt in cerebrovaskularne dogodke) (glejte poglavji 4.5 in 4.8).
In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event).
Pri bolnikih z diseminiranim plazmocitomom je kombinacija lenalidomida in deksametazona povezana z zvečanim tveganjem venske trombembolije (predvsem z globoko vensko trombozo in pljučno embolijo) in arterijske trombembolije (predvsem z miokardnim infarktom in cerebrovaskularnimi dogodki).
In patients with myelodysplastic syndromes and mantle cell lymphoma, treatment with lenalidomide monotherapy was also associated with a risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism), but to a lesser extent than in patients with multiple myeloma – see sections 4.5 and 4.8.
Pri bolnikih z mielodisplastičnimi sindromi in limfomom plaščnih celic je monoterapija z lenalidomidom povezana tudi s tveganjem venske trombembolije (predvsem z globoko vensko trombozo in pljučno embolijo), vendar v manjšem obsegu kot pri bolnikih z diseminiranim plazmocitomom – glejte poglavji 4.5 in 4.8.
In patients with NAGS deficiency, treatment may be started as early as the first day of life and the medicine is used for the patient’s whole life.
Pri bolnikih s pomanjkanjem encima NAGS se lahko zdravljenje začne že prvi dan po rojstvu, zdravilo pa se uporablja celo življenje.
In patients with newly diagnosed CML in chronic phase
Pri bolnikih z novo odkrito KML v kronični fazi
In patients with newly diagnosed dysplasia treated with Simponi, the risks and benefits to the individual patient must be carefully reviewed and consideration should be given to whether therapy should be continued.
Pri bolnikih z novo diagnosticirano displazijo, zdravljenih z zdravilom Simponi, je treba skrbno pregledati tveganja in koristi za posameznega bolnika in razmisliti, ali naj se zdravljenje nadaljuje.
In patients with newly diagnosed multiple myeloma aged 75 years and older who received lenalidomide, there was a higher incidence of serious adverse reactions and adverse reactions that led to treatment discontinuation (see section 4.4).
Pri bolnikih z novo diagnosticiranim diseminiranim plazmocitomom, starih 75 let ali več, ki so prejemali lenalidomid, je bila večja incidenca resnih neželenih učinkov in neželenih učinkov, ki so privedli do prekinitve zdravljenja (glejte poglavje 4.4).
In patients with non-CNS/non-testes extramedullary disease (defined as at least 1 lesion ≥ 1.5 cm) at screening (N = 8/189) clinical response rates (25% [95% CI: 3.2-65.1] were lower compared with patients with no evidence of extramedullary disease (N = 181, 43.6% [95% CI: 36.3 - 51.2]) (see figure 1).
Pri bolnikih, ki so imeli ob presejanju ekstramedularno bolezen brez prizadetosti osrednjega živčevja/brez testisov (opredeljeno kot vsaj 1 sprememba velikosti ≥ 1,5 cm) (n = 8/189) je bil delež kliničnih odzivov manjši (25 % [95 % IZ: 3,2-65,1] kot pri bolnikih brez znakov ekstramedularne bolezni (n = 181, 43,6 % [95 % IZ: 36,3-51,2]) (glejte sliko 1).
In patients with non-functional gastrointestinal or lung neuroendocrine tumours and good prognostic baseline factors, e.g. ileum as primary tumour origin and normal chromogranin A values or without bone involvement, an individual benefit-risk assessment should be performed prior to the start of Afinitor therapy.
Pri bolnikih z nefunkcionalnimi nevroendokrinimi tumorji gastrointestinalnega ali pljučnega izvora in dobrimi izhodiščnimi prognostičnimi dejavniki, kot so ileum kot primarno mesto izvora tumorja in normalne vrednosti kromogranina A ali bolniki brez zajetosti kosti, je treba pred začetkom zdravljenja z zdravilom Afinitor oceniti razmerje med koristmi in tveganji zdravljenja pri vsakem bolniku posamezno.
In patients with non-Hodgkin’s lymphoma and CLL, premedication with glucocorticoids should be considered if MabThera is not given in combination with glucocorticoid-containing chemotherapy.
Če zdravilo MabThera za zdravljenje ne-Hodgkinovega limfoma in kronične limfocitne levkemije ni uporabljeno v kombinaciji s kemoterapijo, ki vključuje glukokortikoid, je treba razmisliti o premedikaciji z glukokortikoidi.
In patients with non-Hodgkin’s lymphoma receiving MabThera in combination with cytotoxic chemotherapy, cases of hepatitis B reactivation have been reported (see non-Hodgkin’s lymphoma).
Pri bolnikih z ne-Hodgkinovim limfomom, ki so prejemali zdravilo MabThera v kombinaciji s citotoksično kemoterapijo, so poročali o primerih reaktivacije virusa hepatitisa B (glejte ne-Hodgkinov limfom).
In patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249) of patients treated with adalimumab.
Pri bolnikih z neinfekcijskim uveitisom so bila protitelesa proti adalimumabu odkrita pri 4,8 % (12/249) bolnikov, ki so jih zdravili z adalimumabom.
In patients with non-transfusion-dependent thalassaemia syndromes, treatment is started when there is evidence of iron overload.
Pri bolnikih s sindromi od transfuzij neodvisne talasemije se zdravljenje začne v primeru dokazane preobremenitve z železom.
In patients with normal renal and hepatic function, a reduction in colchicine dosage or an interruption of colchicine treatment is recommended in co-administration (see section 4.5).
Pri bolnikih z normalnim ledvičnim in jetrnim delovanjem je pri sočasni uporabi priporočeno znižati odmerjanje kolhicina ali zdravljenje s kolhicinom prekiniti (glejte poglavje 4.5).
In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina > 80 ml/min) lahko visoki odmerki nesteroidnih protivnetnih zdravil (NSAID, denimo ibuprofen > 1600 mg dnevno) in acetilsalicilne kisline v visokih odmerkih (> 1,3 g dnevno) zmanjšajo izločanje pemetrekseda in tako lahko povečajo pojavnost neželenih učinkov pemetrekseda.
In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina  80 ml/min) lahko visoki odmerki nesteroidnih protivnetnih zdravil (NSAID-i, denimo, ibuprofen > 1600 mg dnevno) in acetilsalicilna kislina v visokih odmerkih ( 1,3 g dnevno) zmanjšajo eliminacijo pemetrekseda in tako lahko povečajo pojavnost neželenih učinkov pemetrekseda.
In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory medicinal product (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina ≥ 80 ml/min) lahko visoki odmerki nesteroidnih protivnetnih zdravil (NSAIDs, kot je ibuprofen > 1600 mg/dan) in acetilsalicilna kislina v visokih odmerkih (≥ 1,3 g dnevno) zmanjšajo eliminacijo pemetrekseda in tako lahko povečajo pojavnost neželenih učinkov pemetrekseda.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1,600 mg/day) and aspirin at higher dose (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina ≥ 80 ml/min) lahko visoki odmerki nesteroidnih protivnetnih zdravil (NSAID-i, denimo, ibuprofen > 1600 mg dnevno) in acetilsalicilna kislina v visokih odmerkih (≥ 1,3 g dnevno) zmanjšajo eliminacijo pemetrekseda in tako lahko povečajo pojavnost neželenih učinkov pemetrekseda.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher doses (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina ≥ 80 ml/min) lahko visoki odmerki nesteroidnih protivnetnih zdravil (NSAID-i, denimo, ibuprofen > 1600 mg dnevno) in acetilsalicilna kislina v visokih odmerkih (≥ 1,3 g dnevno) zmanjšajo eliminacijo pemetrekseda in tako lahko povečajo pojavnost neželenih učinkov pemetrekseda.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher doses (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina  80 ml/min) lahko visoki odmerki nesteroidnih protivnetnih zdravil (NSAID-i, denimo, ibuprofen > 1600 mg dnevno) in acetilsalicilna kislina v visokih odmerkih ( 1,3 g dnevno) zmanjšajo eliminacijo pemetrekseda in tako lahko povečajo pojavnost neželenih učinkov pemetrekseda.
In patients with normal renal function after hip or knee replacement surgery, receiving dabigatran etexilate and verapamil concomitantly, the dose of Pradaxa should be reduced to 150 mg taken once daily as 2 capsules of 75 mg.
Bolnikom z normalnim ledvičnim delovanjem po operaciji kolka ali kolena, ki so sočasno prejeli dabigatran eteksilat in verapamil, je treba odmerek zdravila Pradaxa zmanjšati na 150 mg enkrat na dan, to je 2 kapsuli po 75 mg enkrat na dan.
In patients with normal renal function after the hip or knee replacement surgery, receiving dabigatran etexilate and verapamil concomitantly, the dose of Pradaxa should be reduced to 150 mg taken once daily as 2 capsules of 75 mg .
Bolnikom z normalnim ledvičnim delovanjem po operativni vstavitvi umetnega kolka ali kolena, ki so sočasno prejeli dabigatran eteksilat in verapamil, je treba odmerek zdravila Pradaxa zmanjšati na 150 mg, to je 2 kapsuli po 75 mg enkrat na dan.
In patients with normal renal function, defined as CLcr > 60 ml/min, zoledronic acid 4 mg/100 ml solution for infusion must not be further diluted.
Za bolnike z normalnim delovanjem ledvic, opredeljenim z očistkom kreatinina > 60 ml/min, se zdravila Zoledronska kislina 4 mg/100 ml raztopina za infundiranje ne sme dodatno redčiti.
In patients with ocular disorders, ophthalmological evaluation should be considered if vision disorder persists or worsens in severity.
Pri bolnikih z motnjami vida, je treba razmisliti o oftalmološkem pregledu, če motnje vida vztrajajo ali se poslabšajo.
in patients with or
gastrointestinalne (GI)
In patients with overactive bladder, characterised by detrusor muscle instability or hyperreflexia, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.
Pri bolnikih s čezmerno aktivnim sečnim mehurjem, za katerega sta značilna nestabilnost detruzorske mišice ali hiperrefleksija, so cistometrične študije pokazale, da oksibutinin povečuje največjo kapaciteto sečnega mehurja in prostornino do prvega krčenja detruzorja.
In patients with overactive bladder, characterised by detrusor muscle instability or hyperreflexia, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.
Pri bolnikih z bolj aktivnim mehurjem, za katere je značilna nestabilnost detruzorske mišice ali povišano refleksivnostjo, so cistometrične študije pokazale, da oksibutinin poviša največjo kapaciteto urinskega mehurja in volumen poveča do prvega skrčenja detruzorja.
In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%) treated with 0.8mg/kg adalimumab monotherapy.
Pri pediatričnih bolnikih s psoriazo so bila protitelesa proti adalimumabu odkrita pri 5/38 oseb (13 %), ki so bile zdravljene z monoterapijo adalimumaba 0,8 mg/kg.
In patients with Paget’s disease symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
Pri bolnikih s Pagetovo boleznijo so poročali o simptomih zaradi nizke koncentracije kalcija v krvi, kot so mišični krči, odrevenelost ali občutek zbadanja, posebno v predelu okrog ust.
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Aclasta administration (see section 4.4).
Pri bolnikih s Pagetovo boleznijo je zelo priporočeno zadostno dodajanje kalcija, ki ustreza vsaj 500 mg elementarnega kalcija, in sicer dvakrat na dan vsaj 10 dni po uporabi zdravila Aclasta (glejte poglavje 4.4).
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following zoledronic acid administration (see section 4.4).
Pri bolnikih s Pagetovo boleznijo je zelo priporočeno zadostno dodajanje kalcija, ki ustreza vsaj 500 mg elementarnega kalcija, dvakrat na dan vsaj 10 dni po uporabi zoledronske kisline (glejte poglavje 4.4).
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic Acid Hospira administration (see section 4.4).
Pri bolnikih s Pagetovo boleznijo je zelo priporočeno zadostno dodajanje kalcija, ki ustreza vsaj 500 mg elementarnega kalcija, in sicer dvakrat na dan vsaj 10 dni po uporabi zdravila Zoledronska kislina Hospira (glejte poglavje 4.4).
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic acid Teva Pharma administration (see section 4.4).
Pri bolnikih s Pagetovo boleznijo je zelo priporočeno zadostno dodajanje kalcija, ki ustreza vsaj 500 mg elementarnega kalcija, in sicer dvakrat na dan vsaj 10 dni po uporabi zdravila Zoledronska kislina Teva Pharma (glejte poglavje 4.4).
In patients with Paget’s disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
Pri bolnikih s Pagetovo boleznijo so poročali o simptomih zaradi nizke koncentracije kalcija v krvi, kot so mišični krči, odrevenelost ali občutek zbadanja, posebno v predelu okrog ust.
In patients with Paget’s disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
Pri bolnikih s Pagetovo boleznijo: imptomi zaradi nizke koncentracije kalcija v krvi, kot so mišični krči, odrevenelost ali občutek zbadanja, posebno v predelu okrog ust.
In patients with Paget’s disease: symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
Pri bolnikih s Pagetovo boleznijo so poročali o simptomih zaradi nizke koncentracije kalcija v krvi, kot so mišični krči, odrevenelost ali občutek zbadanja, posebno v predelu okrog ust.
In patients with PAH, this mechanism is overactive and, by blocking the receptors, macitentan helps widen the arteries in the lungs and thereby bring down the blood pressure.
Ta mehanizem je pri bolnikih s PAH čezmerno dejaven, zato macitentan z zaviranjem omenjenih receptorjev pomaga razširiti pljučne arterije in s tem znižati krvni tlak.
In patients with parathyroid carcinoma or primary hyperparathyroidism, the recommended starting dose of Cinacalcet Mylan for adults is 30 mg twice a day.
Pri bolnikih s paratiroidnim karcinomom ali primarnim hiperparatiroidizmom je priporočeni začetni odmerek zdravila Cinakalcet Mylan za odrasle 30 mg dvakrat na dan.
In patients with parathyroid carcinoma or primary hyperparathyroidism, the recommended starting dose of Mimpara for adults is 30 mg twice a day.
Pri bolnikih s paratiroidnim karcinomom ali primarnim hiperparatiroidizmom je priporočeni začetni odmerek zdravila Mimpara za odrasle 30 mg dvakrat dnevno.
In patients with parathyroid carcinoma or primary hyperparathyroidism, the side effects are similar to those seen in patients with long-standing kidney disease - the most frequent side effects are nausea and vomiting.
Pri bolnikih s paratiroidnim karcinomom ali primarnim hiperparatiroidizmom so neželeni učinki podobni tistim, opaženim pri bolnikih z dolgotrajnim ledvičnim obolenjem: najpogostejša neželena učinka sta navzeja (slabost) in bruhanje.
In patients with Parkinson's disease Olanzapine Mylan may worsen the symptoms.
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo OLANZAPIN MYLAN poslabša simptome.
In patients with Parkinson’s disease and related diseases, and in patients with dementia with Lewy bodies, there is typically a loss of nerve cells in the striatum containing dopamine.
Pri bolnikih s Parkinsonovo boleznijo in povezanimi obolenji ter bolnikih z demenco z Lewyjevimi telesci gre navadno za izgubo živčnih celic v striatumu, ki vsebujejo dopamin.
In patients with Parkinson’s disease Olanzapine Glenmark Europe may worsen the symptoms
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo Olanzapin Glenmark Europe poslabša simptome.
In patients with Parkinson’s disease Olanzapine Glenmark may worsen the symptoms.
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo Olanzapin Glenmark poslabša simptome.
In patients with Parkinson’s disease Olazax Disperzi may worsen the symptoms
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo Olazax Disperzi poslabša simptome.
In patients with Parkinson’s disease Olazax may worsen the symptoms
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo Olazax poslabša simptome.
In patients with Parkinson’s disease, certain cells in the brain that produce dopamine die, and as dopamine is involved in controlling movement, the patient's movement worsens over time.
Pri bolnikih s Parkinsonovo boleznijo določene celice v možganih, ki tvorijo dopamin, odmrejo in ker dopamin sodeluje pri nadzoru gibanja, se bolnikova sposobnost gibanja sčasoma poslabša.
In patients with Parkinson’s disease, multiple-dose pharmacokinetics was comparable to single-dose pharmacokinetics, i.e. there was a minimal accumulation of levodopa from the modified-release levodopa/carbidopa medicinal product.
Pri bolnikih s Parkinsonovo boleznijo je bila farmakokinetika večkratnih odmerkov primerljiva s farmakokinetiko enkratnih odmerkov, tj. prišlo je do minimalnega kopičenja levodope iz zdravila s prirejenim sproščanjem, ki vsebuje levodopo/karbidopo.
In patients with Parkinson’s disease, the cells in the brain that produce dopamine (a substance used to transmit signals between nerve cells that help to control muscle movement) begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo pričnejo celice, ki proizvajajo dopamin (snov, ki prenaša signale med živčnimi celicami, ki pomagajo pri nadzoru mišičnih gibov), odmirati, zato se količina dopamina v možganih zmanjša.
In patients with Parkinson’s disease, the cells in the brain that produce dopamine, a neurotransmitter important for controlling movement, begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo začnejo celice v možganih, ki proizvajajo dopamin, tj. živčni prenašalec, pomemben za nadzorovanje gibov, odmirati, zato se količina dopamina v možganih zmanjša.
In patients with Parkinson’s disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo začnejo celice v možganih, ki proizvajajo živčni prenašalec dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
In patients with Parkinson’s disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo začnejo celice v možganih, ki tvorijo živčni prenašalec dopamin, odmirati, količina dopamina v možganih pa se zmanjša.
In patients with Parkinson’s disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
Parkinsonovo boleznijo začnejo celice, ki proizvajajo dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
In patients with Parkinson’s disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo pričnejo celice, ki proizvajajo dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
In patients with Parkinson’s disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo začnejo celice, ki proizvajajo dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
In patients with Parkinson’s disease, the cells that produce dopamine die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo celice, ki proizvajajo dopamin, odmirajo, zato se količina dopamina v možganih zmanjša.
In patients with Parkinson’s disease, the following side effects are also seen in more than 1 patient in 10: dizziness, dyskinesia (difficulty controlling movement) and somnolence (sleepiness).
Pri bolnikih s Parkinsonovo boleznijo so bili pri več kot 1 od 10 bolnikov opaženi naslednji neželeni učinki: omotica, diskinezija (težave z nadzorovanjem gibanja) in somnolenca (zaspanost).
In patients with persistent very good partial response, consider other methods to evaluate the depth of response.
Pri bolnikih z dolgotrajnim zelo dobrim delnim odzivom, je treba razmisliti o uporabi drugih metod za oceno globine odgovora.
in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia
uporabe bosutiniba pri bolnikih s kronično mieloično levkemijo s prisotnim
In patients with PNH and aHUS the complement proteins are over-activated and cause damage to the patients’ own blood cells.
Pri bolnikih s paroksizmalno nočno hemoglobinurijo in atipičnim hemolitično-uremičnim sindromom so beljakovine komplementa preveč dejavne, kar škoduje njihovim lastnim krvnim celicam.
In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti- adalimumab antibodies were identified in 15.8% (27/171) of patients treated with adalimumab.
Med bolniki s poliartikularnim juvenilnim idiopatskim artritisom, ki so bili stari od 4 do 17 let, so protitelesa proti adalimumabu ugotovili pri 15,8 % (27/171) bolnikov, ki so dobivali adalimumab.